Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Estrogen Receptor-Positive Breast Carcinoma”

670 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 670 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT05262400
What this trial is testing

Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors

Who this might be right for
Breast CancerSolid Tumors
Pfizer 235
Testing effectiveness (Phase 2)Study completedNCT03184090
What this trial is testing

Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ mBC

Who this might be right for
Metastatic Breast Cancer
MedSIR 33
Large-scale testing (Phase 3)Study completedNCT01564056
What this trial is testing

Adjuvant Systemic Treatment for (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment

Who this might be right for
Breast Cancer
UNICANCER 1,989
Testing effectiveness (Phase 2)Looking for participantsNCT06150898
What this trial is testing

Ketorolac and Pregabalin Effects on breaSt Cancer (KePreSt)

Who this might be right for
Early-stage Breast CancerEstrogen-receptor-positive Breast Cancer
Jules Bordet Institute 112
Testing effectiveness (Phase 2)Study completedNCT00234403
What this trial is testing

A Trial to Evaluate the Combination of Iressa & Faslodex® in Patients With Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
AstraZeneca 60
Large-scale testing (Phase 3)Not Yet RecruitingNCT07153757
What this trial is testing

De-escalation Therapy in Stage I ER-Positive Breast Cancer: A Non-Inferiority Trial

Who this might be right for
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Fudan University 2,934
Testing effectiveness (Phase 2)Study completedNCT02273973
What this trial is testing

Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI)

Who this might be right for
Breast Cancer
Genentech, Inc. 334
Large-scale testing (Phase 3)Looking for participantsNCT06195709
What this trial is testing

ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients

Who this might be right for
Breast Carcinoma
Institut Curie 300
Testing effectiveness (Phase 2)Study completedNCT03054363
What this trial is testing

Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer

Who this might be right for
Breast Cancer
University of Colorado, Denver 42
Large-scale testing (Phase 3)Active Not RecruitingNCT05104866
What this trial is testing

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

Who this might be right for
Breast Cancer
AstraZeneca 732
Early research (Phase 1)Active Not RecruitingNCT04993430
What this trial is testing

HRS8807 Monotherapy and in Combination With SHR6390 in Subjects With ER-Positive, HER2-Negative Metastatic or Locally Advanced Breast Cancer

Who this might be right for
ER-Positive, HER2-Negative Breast Cancer
Shanghai Hengrui Pharmaceutical Co., Ltd. 46
Testing effectiveness (Phase 2)UnknownNCT04488107
What this trial is testing

Safety, Tolerability, Pharmacokinetics and Antitumor Activity of FCN-437c

Who this might be right for
Breast Neoplasms
Ahon Pharmaceutical Co., Ltd. 78
Not applicableEnded earlyNCT01856036
What this trial is testing

Anti-Tumor Immunity Induced by Cryoablation of Invasive Breast Cancers

Who this might be right for
Breast Cancer
Saint John's Cancer Institute 2
Testing effectiveness (Phase 2)Study completedNCT02718144
What this trial is testing

Assessment of Safety and Efficacy of Estetrol in Postmenopausal Women With Advanced Estrogen Receptor Positive (ER+) Breast Cancer

Who this might be right for
Breast Neoplasms
Pantarhei Oncology B.V. 12
Testing effectiveness (Phase 2)UnknownNCT04997798
What this trial is testing

Dalpiciclib in Combination With Exemestane and Trastuzumab Plus Pyrotinib in Early Triple Positive Breast Cancer

Who this might be right for
Breast CancerEstrogen Receptor Positive TumorHER2-positive Breast Cancer
First Affiliated Hospital of Zhejiang University 30
Testing effectiveness (Phase 2)Ended earlyNCT02000375
What this trial is testing

A Phase II Study Evaluating the Role of Androgen Receptors as Targets for Therapy of Pre-treated Post-menopausal Patients With ER/PgR-negative/AR-positive or ER and/or PgRpositive/ AR-positive Metastatic Breast Cancer (ARTT)

Who this might be right for
Metastatic BreastcancerEstrogen Receptor Positive Breast CancerEstrogen Receptor Negative Neoplasm+3 more
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 20
Testing effectiveness (Phase 2)Ended earlyNCT01394211
What this trial is testing

Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer

Who this might be right for
Estrogen Receptor-positive Breast CancerHuman Epidermal Growth Factor 2 Negative Carcinoma of BreastMale Breast Cancer+4 more
University of Arizona 2
Testing effectiveness (Phase 2)WithdrawnNCT04038489
What this trial is testing

COX Inhibition and Biomarkers During Neoadjuvant Chemoendocrine Therapy for ER+, HER2- Stage I-III Breast Cancer

Who this might be right for
Breast CancerEstrogen Receptor-positive Breast Cancer
University of Virginia
Testing effectiveness (Phase 2)Study completedNCT05163106
What this trial is testing

Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole

Who this might be right for
Breast CancerHER2-negative Breast CancerER-positive Breast Cancer+3 more
University Hospital, Akershus 85
Large-scale testing (Phase 3)Study completedNCT00390455
What this trial is testing

Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive

Who this might be right for
Estrogen Receptor PositiveHER2 Positive Breast CarcinomaHER2/Neu Negative+5 more
National Cancer Institute (NCI) 295
Next Page